Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review.

摘要: PURPOSE: Since the increased use of first-line chemotherapy for non–small-cell lung cancer (NSCLC), second-line may nowadays be considered a growing group patients. Guidelines treatment have to developed yet. METHODS: We reviewed published literature on NSCLC with emphasis role factors such as pretreatment, response treatment, and length disease-free-interval. RESULTS: Thirty-four single-agent-studies 24 multidrug-studies were identified. Docetaxel has been studied most extensively is only agent that in randomized phase III trials. Different definitions sensitivity applied by different authors conflicting results reported about influence prior chemotherapy. CONCLUSION: patients are treated platinum-based regimen first line, platinum resistance usually major consideration seco...